Latest / Psychopharmacology Today / Ep. 12: Start Low and Go Slow: Understanding Psychotropic Drug Interactions
Transcript
- 0:04Our learning objectives are, I'm going to look at
- 0:07the pharmacokinetics and pharmacodynamic mechanisms underlying psychotropic drug
- 0:12interactions, just as background.
- 0:15I'm going to hopefully identify the major CYP450 pathways that are involved,
- 0:21the major pathways, I should say,
- 0:23with psychotropic metabolism. We're going to recognize high-risk drug combinations
- 0:28in psychiatry, which really result in some very serious adverse drug effects.
- 0:33Evaluate the interactions involving antidepressants,
- 0:36antipsychotics, mood stabilizers,
- 0:38benzodiazepines, and stimulants with substance
- 0:41use disordered medications such as AOUD and medications for the use
- 0:45of opioid use disorder, et cetera.
- 0:47And then we'll look at the NA clinical algorithm to safely manage psychotropic
- 0:52prescribing that I've given ~ over ~ several sessions with ~ psychiatrists
- 0:58and other physicians, prescribers that is.
- 1:00If we look at the overview, the drug-to-drug interactions involving psychotropic
- 1:04medications are among the most common adverse drug reactions that we have that lead
- 1:09to treatment failure and also medication-related hospitalizations
- 1:14in both psychiatric and addiction medicine practice.
- 1:17As being a forensic pharmacist for many years ~ in the legal system
- 1:24of malpractice cases, specifically death cases,
- 1:26I've had more interactions and more
- 1:29situations around drug-to-drug interactions with this.
- 1:33And that's why I think it's so important to me for people to keep up and
- 1:36be aware of this. We hope that the seminar will provide advanced clinical
- 1:40understanding of both pharmacokinetic and pharmacodynamic interactions amongst
- 1:45the classifications. The emphasis will be placed on the cytochrome P450 system
- 1:51as it relates to metabolism, the transporter systems,
- 1:54the pharmacogenetics we'll mention briefly.
- 1:56Interaction management with these medically complex patients,
- 2:00as y'all know. Practitioners will hopefully learn to identify,
- 2:03predict, and manage these clinically significant interactions using evidence-based
- 2:08prescribing strategies. Our first objective is to explain
- 2:12the pharmacokinetic and pharmacodynamic mechanisms that
- 2:16are underlying the psychotropic interactions.
- 2:18Pharmacokinetics, ~ simply put,
- 2:21I call it the "body-to-drug." It is what the body does to a drug.
- 2:26So I just simply say pharmacokinetics are absorption and distribution
- 2:30and metabolism and elimination.
- 2:33In psychiatry, the most clinically important pharmacokinetic interactions involve
- 2:37the heptic, the liver, ~ CYP450 metabolism system,
- 2:42along with drug transports, also the renal clearance and protein binding.
- 2:47In pharmacology and psychopharm,
- 2:48which a lot of you are already trained in,
- 2:50that is why it's so important to understand not only
- 2:53the liver metabolism components,
- 2:55but the renal clearance and protein binding.
- 2:58FDA drug interaction resources emphasize CYP enzymes and transport systems
- 3:04as major determinants of clinically significant drug interactions.
- 3:07Let's look at absorption. Absorption interactions occur when one drug
- 3:10changes
- 3:10how another drug enters the bloodstream.
- 3:12And the examples of this, as it relates to,
- 3:15are antacids or supplements that may reduce the absorption of some,
- 3:21if not a majority of that. If it be calcium-based antacids or whatever it may be,
- 3:27it can block that. Food can increase or decrease absorption depending on the drug,
- 3:31and that's why you take them on an empty stomach or two hours
- 3:34before a meal or with the meal,
- 3:36that's extremely important. And I want to train ~ prescribing psychologists
- 3:42to understand how important that is.
- 3:44Delayed gastric emptying may also alter the onset of action.
- 3:48And of course alcohol would interact with just about every psychotropic medication
- 3:53that we have available on the current market.
- 3:56And it can increase absorption and cause CNS toxicity,
- 4:01especially as it relates to other sedatives such as benzodiazepines.
- 4:05Distribution ~ interactions occur when drugs compete for plasma protein binding
- 4:11or alter tissue distribution. I could spend a whole hour discussing this,
- 4:15but the thing about it is the most relevant is the highly protein drugs such
- 4:20as valproate. ~ UpToDate, and most of y'all are familiar with UpToDate,
- 4:25it will tell you about the protein binding components
- 4:29of various medications, especially the psychotropics.
- 4:32So valproate and your SSRIs and some of your tricyclics and some
- 4:37of your antipsychotics. Because increased free drugs,
- 4:41when it's not protein-bound, can increase toxicity.
- 4:44And there are many protein-binding interactions that are transient
- 4:49and clinically important, mainly when you combine them with impaired metabolism
- 4:53or elimination. And we'll talk a little more about that.
- 4:56Metabolism, and we'll talk a lot about this metabolism,
- 4:59but it's the most important mechanism for psychotropic drug interactions.
- 5:03And the major pathways include the CYP2D6,
- 5:072C19, 3A4/5,
- 5:11~ 1A2, 2B6, 2C9,
- 5:15and others. So the thing about it is that metabolism is important.
- 5:19The more common ones that we see are fluoxetine
- 5:23and paroxetine involve CYP2D6,
- 5:27~ and they can increase levels of the tricyclics,
- 5:30some of the antipsychotics, especially the second generation ~ Strattera
- 5:37and other drugs such as that. Fluvoxamine,
- 5:39which was removed from the market for a number of years and now is back on,
- 5:42will interfere with 1A2.
- 5:44And its fact that it interferes with a lot of the antipsychotics,
- 5:48clozapine being one, olanzapine being the second one.
- 5:52Carbamazepine ~ is in fact ~ induced by 3A4 and can lower concentrations
- 5:58of other antipsychotics, antidepressants,
- 6:01benzos. And smoking induces the 1A2 and so it lowers clozapine
- 6:06and olanzapine levels. Smoking cessation can raise the levels
- 6:10and increase toxicity risk. And then the herbals,
- 6:12and one of the more common herbals that we see that involves metabolism is St.
- 6:16John's wort, which affects the 3A4.
- 6:20And also it reduces the levels ~ of multiple medications.
- 6:25It also, when it's combined with tobacco smoking and grapefruit juice...
- 6:29Now let me talk about grapefruit juice.
- 6:31I don't say a lot about it except right here.
- 6:33It's okay to take grapefruit juice with medications as long as it's three hours'
- 6:36difference.
- 6:37So they can take a medication and take ~ grapefruit juice three hours later.
- 6:41In fact, I encourage the use of grapefruit juice now because
- 6:44of neuroinflammation that we're discovering.
- 6:46And grapefruit juice, especially the ruby red grapefruit juice,
- 6:50is a great anti-inflammatory. So the thing about it is be aware.
- 6:54But it has to be taken three hours after the drug may be.
- 6:58And then elimination. And the elimination interactions are especially important when
- 7:02the drug is cleared by your kidneys.
- 7:04And of course, as we know that lithium being the primary one that we look at;
- 7:08~ levels can increase with thiazide diuretics,
- 7:12ACE inhibitors, ARBs, non-steroidal anti-inflammatories,
- 7:15it can lead to dehydration and significant renal impairment.
- 7:20And then gabapentin, pregabalin,
- 7:23acamprosate, ~ and lithium require renal dose consideration.
- 7:28So if these drugs are going to be prescribed or used by you,
- 7:31you need to definitely make sure you have a good renal clearance consideration.
- 7:35And reduced clearance doesn't mean you can't give it,
- 7:38it's just you have to determine what your dose may be.
- 7:40But it does increase the risk for sedation,
- 7:43tremor, and some other toxicities.
- 7:46When we look at pharmacogenomics,
- 7:46the genetic variations can mimic drug interactions.
- 7:50I've been on the bandwagon for pharmacogenomics for forever
- 7:54because of a personal issue with my son years ago.
- 7:57A patient who is a 2D6 poor metabolizer may have high exposure
- 8:02to certain antidepressants, antipsychotics,
- 8:04even without interacting drugs.
- 8:06And so if you have these different metabolisms,
- 8:09the poor metabolism, the fast metabolizer,
- 8:12the non-metabolizer, you can have some very serious interactions.
- 8:17So that is a part of this consideration that needs to be looked at as a part
- 8:21of the evaluation process.
- 8:23When you look at pharmacodynamics,
- 8:25now what I talk about pharmacodynamics,
- 8:27it is what the drug does to the body.
- 8:29And so what this means, these interactions,
- 8:32when you have two or more of the drugs that can produce additive,
- 8:35one plus one equals three; they could be synergistic,
- 8:38one plus one equals four; or opposing effects at the receptor level,
- 8:43at ion channel levels, neurotransmitter levels,
- 8:45organ systems, or all of them.
- 8:47And so the thing about it is it has to be considered.
- 8:50When we look at the pharmacodynamic,
- 8:52the more common ones that we see are additive with the psychotropics.
- 8:57And it leads to depression. This is one of the more dangerous pharmacodynamic
- 9:01interactions in addiction psychiatry,
- 9:03according to that particular profession and that specialty.
- 9:07The high-risk combinations include the benzodiazepines and opioids,
- 9:11which most of y'all are familiar with,
- 9:13benzodiazepines and alcohol. You know,
- 9:16opioids are
- 9:17one plus one equals four; benzos and alcohols,
- 9:20one plus one equals three, ~ methadone or buprenorphine plus any
- 9:25of your sedative hypnotics, your benzos and your antipsychotics,
- 9:29the gabapentins and the opioids,
- 9:32and then of course the Z drugs and alcohols.
- 9:35So these lead to more depression and more stupor and those types of things.
- 9:39So the risks that you run when you have those particular interactions is sedation.
- 9:44If you got an individual who's over 50,
- 9:47you'll end up with increased risk for falls.
- 9:49There can be cognitive impairment,
- 9:51there can be respiratory depression,
- 9:53and if it's opioids involved, as most of you know,
- 9:56it can lead to an overdose death.
- 9:59And then the other thing is the serotonin toxicity,
- 10:02which occurs when serotonic effects become excessive.
- 10:05And this is when we have these high-risk combinations,
- 10:08these cocktails
- 10:09that I run into all the time where people are taking SSRIs or SNRIs,
- 10:14and MAOIs, and then you have SSRIs and linezolid,
- 10:20and we have ~ methylene blue for some kind of lab test that you have.
- 10:25And the two things that I will tell you to be aware of with the SSRIs
- 10:30and SNRIs is if a patient is given tramadol
- 10:33or if they take an over-the-counter cough syrup that has dextromethorphan in it.
- 10:37And the thing about it is it can create significant serotonergic responses
- 10:41in certain individuals. So these individuals have to be carefully monitored.
- 10:46And now, you know, we're talking about psychedelics being used in
- 10:51the management of resistant depression and all.
- 10:53And here we have SSRIs and SNRIs along with MDMA.
- 10:58And I know people say
- 10:59the FDA has rejected it originally,
- 11:01but now it's been reintroduced.
- 11:02So as we see the use of these psychotropics,
- 11:05and I haven't had time to put that together,
- 11:07but that is something to be considered when we look at the psychedelics too.
- 11:10When you see these combinations,
- 11:12it causes agitation, it creates tremor,
- 11:15hyperreflexia, clonus, which is the movement or rapid movement of muscles,
- 11:19especially in the feet and the hands,
- 11:21where you see them move; diaphoresis,
- 11:23fever, diarrhea,
- 11:25and confusion. So the thing about it is it could be very,
- 11:28very uncomfortable for the patient.
- 11:30The other pharmacodynamic interaction that we've got to be aware of
- 11:33is the QT prolongation and torsades risk.
- 11:36And so several of the psychotropics prolong the ventricle repolarization.
- 11:41I'll get into more specifics of this in just a few minutes.
- 11:44The risk increases when multiple QT-prolonging drugs are combined
- 11:48or drug levels rise through the CYP inhibition.
- 11:52So you got to know about inhibitors and inducers that we're going to talk about
- 11:55in a second. And there are a lot of APA educational resources that emphasize
- 11:59QTc monitoring, patient-specific risk factors,
- 12:02electrolyte abnormalities. Lab tests are going to be extremely important,
- 12:06especially when it comes to any kind of QTc monitoring,
- 12:10especially your potassium, your calcium,
- 12:12and your chloride. So the thing about it is you have to look at that.
- 12:15And then careful medication selection.
- 12:18By themselves, these are the high-risk drugs that can lead to QT prolongation.
- 12:23Number one on the hit parade is methadone.
- 12:25And then we have the other antipsychotics almost across the board.
- 12:29Haloperidol IV, we have to be extremely careful with it in the ER
- 12:34and also in hospital settings because of that,
- 12:37especially if there's a previous risk.
- 12:39And then citalopram, escitalopram,
- 12:42and TCAs, those antidepressants can also do it.
- 12:45And also you have it with some of your antibiotics,
- 12:49and other antiemetics. And so the thing about it is you need to be aware
- 12:53of the drugs. The reason that the pharmacy went from a bachelor's degree,
- 12:58a five-year degree, to a doctoral degree is because of this very issue.
- 13:03One of the major issues of
- 13:04prolonging education for pharmacists many years ago was because we have over
- 13:09400 drugs that create these problems.
- 13:11When we look at the risk factors for this it can be usually a female,
- 13:15can be older, over 50, ~ hypokalemia,
- 13:18hypomagnesemia, bradycardia, structural heart disease.
- 13:22When we talk about high methadone dose,
- 13:24I'll mention that
- 13:25anything over 80 milligrams is considered high methadone dose as it relates
- 13:30to ~ QTc monitoring. So be aware of that.
- 13:33And then when you add these multiple QT-prolonging medications that
- 13:37we just mentioned, it can create that issue too.
- 13:39And then we have what some people don't know about is the anticholinergic burden.
- 13:44You can have anticholinergic toxicities,
- 13:47~ especially when you're ~ using
- 13:51first-generation antidepressants such as the tricyclic antidepressants.
- 13:54Being a chronic pain
- 13:56management specialist, one of the things that we've run into with this
- 13:59a good bit has been the use of amitriptyline in pain patients.
- 14:03And so we've got to be aware of that.
- 14:05And then we got paroxetine and ~ clozapine and olanzapine and other antipsychotics.
- 14:11And we got some of the antihistamines that are used,
- 14:14diphenylhydramine, and some of the things that we use as ~ antimuscarinics
- 14:20for ~ bladder control. When we see these types of anticholionergic effects,
- 14:25toxicities, you have dry mouth,
- 14:27constipation, urinary retention,
- 14:29blurred vision, you can have ~ tachycardia and it can have either atrial form
- 14:35to it or ventricle tachyform ~
- 14:38like an AFib, but the thing about it is it's one of those things that
- 14:41can be confused and some people get misdiagnosed.
- 14:43I have a lot of people get misdiagnosed that are using these types
- 14:47of medications when it comes to this as a result of that ~ tachycardia.
- 14:52Confusion and falls and delirium.
- 14:55And that's one of the things that we need to look at.
- 14:57And then another thing that we run into,
- 14:59y'all, is the dopamine blockade and extrapyramidal toxicities that y'all
- 15:03are more familiar with when we talk about mainly a lot of the antipsychotics
- 15:08and the combination of antipsychotics with other antipsychotics or
- 15:11lithium. And what we see is acute dystonia,
- 15:15Parkinsonism, tardive dyskinesia,
- 15:18~ and of course the thing that seems to be really significant recently,
- 15:23at least in my world,
- 15:24is neuroleptic malignant syndrome.
- 15:26And so the thing about it is again,
- 15:28the dopamine blockade and extrapyramidal toxins,
- 15:31and of course, you then have those medications we use to treat those symptoms.
- 15:35The other issue that we find in the pharmacodynamic world when
- 15:39it comes to psychotropics is seizure threshold lowering.
- 15:41Some psychotropics lower the seizure threshold,
- 15:44especially in overdose or substance withdrawal,
- 15:47and that's why you will see
- 15:49these types of seizures when these medications are stopped abruptly,
- 15:54wellbutrin being one. I've seen this a lot in adolescents when they
- 15:58had stopped taking their wellbutrin or their stimulant.
- 16:02But you can have wellbutrin and a stimulant and wellbutrin and alcohol.
- 16:06And when people lower their alcohol consumption,
- 16:09you can have these types of seizures.
- 16:11Clozapine...
- 16:12Tramadol again comes up again and again in these different types of interactions.
- 16:19When you add ~ tramadol, and with first generation or some of the SSRIs,
- 16:25SNRI antidepressants. And of course,
- 16:28stimulants; when you add more than one stimulant at a time,
- 16:31it can create that. And also ~ antipsychotics and severe electrolyte disturbance,
- 16:37like you have sodium,
- 16:39calcium, ~ potassium ratios are altered.
- 16:42Again, the lab work is going to be extremely important when you look
- 16:45at electrolytes and making these types of determinations.
- 16:48And then simply the opposing pharmacodynamic effects.
- 16:52Some drugs reduce the intended effect of the other drug.
- 16:55Stimulants worsen anxiety, insomnia and psychosis,
- 16:59the dopamine-blocking antipsychotics may blunt dopaminergic
- 17:03treatments such as being used ~ for Parkinson's.
- 17:06~ Sedatives may worsen depression,
- 17:09cognition, ~ and recovery engagement.
- 17:12And naltrexone blocks opioid antagonists and can precipitate withdrawal.
- 17:18Sometimes people start naltrexone with opioids on board and create
- 17:22a withdrawal syndrome which can be very significant.
- 17:25So what do you do? When you look at pharmacodynamic interactions,
- 17:28~ they can be evaluated in two steps.
- 17:31~ One, the question is will this combination change drug concentration?
- 17:36The pharmacokinetic question of the CYP450 inhibition,
- 17:41or if it's CYP induction, or if there's a renal clearance issue,
- 17:46or if there's a hepatic impairment issue,
- 17:48~ if they have something to do with the transport
- 17:51effects or the pharmacogenomics.
- 17:53So it is a complicated question to answer,
- 17:56but the thing about it is, it is something that makes this particular keeping
- 18:00up with these drug interactions extremely difficult sometimes.
- 18:03And the second question is will this combination increase clinical toxicity
- 18:07or reduce therapeutic effect? This is the pharmacodynamic question,
- 18:10sedation. Now that's the one thing that we've got to be really aware
- 18:15of when we're giving these psychotropics is what does the
- 18:18sedation impairment look like?
- 18:20What is the serotonin toxicity?
- 18:22Does it produce a QT prolongation issue?
- 18:26~ Respiratory depression, anticholinergic burden,
- 18:31seizure risk, dopamine blockade,
- 18:34withdrawal precipitation. So if you have your checklist on your medication sheet,
- 18:40and we've added this to a lot of the medication,
- 18:42we actually have them where there's a history of if there's any problems with this.
- 18:47The safest prescribing approach is to combine medication reconciliation,
- 18:52a CYP pathway review, which there's resources to be able to do that,
- 18:56pharmacodynamic risk screening,
- 18:58which they also have resources to do that,
- 19:00patient-specific risk factors,
- 19:03which I just went over, generally speaking.
- 19:05ECG and lab monitoring, lab reports,
- 19:09when indicated, and a close follow up after any medication change.
- 19:13That's the thing about psychiatry that I
- 19:16just scream about, as it is in medicine.
- 19:19I just had a question from my son today that they-
- 19:21he's on a hormonal therapy and an antidepressant;
- 19:24went to a psychiatric nurse practitioner;
- 19:27she wanted to do a complete withdrawal of all the medications for at least
- 19:3230 to 45 days. And I told him,
- 19:34"Absolutely not!"
- 19:36You only do one at a time. You don't do them all at one
- 19:39time. So let's mention the CYP450 pathways that are involved
- 19:43in the psychotropic drug metabolism.
- 19:46So the cytochrome 450 enzyme system is responsible for
- 19:49the metabolism of approximately 70/80% of all clinical prescribed medications,
- 19:55including most antidepressants,
- 19:56antipsychotics, mood stabilizers,
- 19:58anxiolytics, hypnotics, stimulants,
- 20:01and several medications used in the treatment of substance use disorders.
- 20:05The variability in the CYP450 activity,
- 20:08whether or not due to genetics or drug interaction,
- 20:11age, liver disease, smoking, or diet,
- 20:13is one of the leading causes of adverse drug effects,
- 20:17therapeutic failure and medication-related hospitalization in psychiatric practice.
- 20:21If you don't remember anything else tonight,
- 20:23remember that. Understanding CY450 metabolism enables clinicians
- 20:29to anticipate possible drug interactions,
- 20:32individualize medication selection,
- 20:35optimize what the dose is, of course,
- 20:37you go low and you go slow, and you improve patient safety.
- 20:41So if you get good at this,
- 20:43you can head off some problems in the field.
- 20:45So simply put, as we look at the research,
- 20:48these are the anticipated contributions to metabolism.
- 20:52The CYP3A4/5, 30 to 40 percent as it relates to those particular drugs there.
- 20:59~ 2D6, 20 to 25%;
- 21:02your antidepressants and some of your antipsychotics.
- 21:05The 2C19, 8–10%; 1A2, 5–10%;
- 21:092B6, 3–5%, and 2C9, 5%.
- 21:13You kinda see that and then the UGT pathways,
- 21:16variable. The 3A4/5 is the most abundant
- 21:20hepatic and intestinal CYP enzyme available,
- 21:24and thus it metabolizes nearly one-third of all prescription
- 21:29and over-the-counter medications that we know about.
- 21:32But the major substrates that it metabolizes have to do with your antipsychotics,
- 21:39wellbutrin, your benzodiazepines,
- 21:42collectively speaking. And then when we look at methadone and then buprenorphine.
- 21:47So your 3A4 is a big player with a majority of some of these medications,
- 21:53as you can tell. So the clinical significance of what we call-
- 21:56now we're going to talk about inhibitors and inducers.
- 21:59So let's talk about what an inhibitor is.
- 22:01Inhibition increases plasma drug concentrations and toxicity,
- 22:06where induction lowers concentrations
- 22:09and may result in therapeutic failure.
- 22:11So inhibition increases drug concentrations.
- 22:15Induction lowers the concentration,
- 22:18and it may result in a lower, ~ below-therapeutic ~ dose.
- 22:23So when we look at the inhibitors and what they do,
- 22:26the strong 3A4 inhibitors are a lot of your antibiotics,
- 22:31some of your antiviral drugs,
- 22:34and grapefruit juice. And there's grapefruit juice again.
- 22:37And so the thing about it is you want to make sure that these drugs
- 22:40are taken separately from any of the other medications that may be prescribed.
- 22:46And so when you're looking at your med histories and you're looking
- 22:49at the inhibitions, these are the ones that you really need to look at very closely.
- 22:53An inducer is a medication, herbal product,
- 22:56or environmental substrate that increases the production or activity of
- 22:59one or more CYP450 enzymes.
- 23:02As enzyme activity increases, drugs metabolized by those enzymes
- 23:06are broken down more rapidly, often resulting in lower blood concentrations,
- 23:11a reduced therapeutic effect, or treatment failure totally.
- 23:14So this is the inducers. So you've got inhibitors and inducers.
- 23:19And these are the inducers:
- 23:21Carbamazepine is a big player;
- 23:24Phenytoin; phenobarbital. I know phenobarbital is an old barbiturate,
- 23:28but they're starting to use it more in ambulatory detox,
- 23:33and of course they're still using it as an anti-seizure medication.
- 23:36A tuberculosis drug, St. John's wort,
- 23:39~ Kava Kava, Valerian root.
- 23:43I mean, there's a whole list of these.
- 23:45But these are the inducers. They can create treatment failure,
- 23:49actually. When we look at 2D6,
- 23:51it metabolizes about 20–25% of psychotropic meds despite representing only
- 23:56a small fraction of the total CYP content.
- 23:58And the ones that it impacts are the ones that we prescribe the most:
- 24:03fluoxetine, ~ paroxetine,
- 24:06duloxetine, atomoxetine, reciprodone,
- 24:09aripiprazole, Haldol, and the TCAs.
- 24:12So the thing about it is 2D6, even though it's a very small percentage
- 24:17of the CYP enzyme system, it metabolizes about a quarter of the psychotropics,
- 24:22and these are the ones that are prescribed a great deal.
- 24:25The strong inhibitors of the 2D6,
- 24:28again, they increase the toxicity rate,
- 24:31is fluoxetine, ~ and Paxil and wellbutrin and
- 24:37the old cardiac medication, quinidine.
- 24:39In fact, that's why we stopped using quinadine a great deal,
- 24:42is because of this issue. When we have 2D6,
- 24:46it exhibits marketed genetic polymorphism.
- 24:49So you can have, when you do your genomics,
- 24:52the poor metabolism increased drug exposure and adverse effects.
- 24:56The intermediate metabolizers have modestly increased exposure and some effects.
- 25:01Normal metabolizers may have what we would consider expected pharmacokinetics.
- 25:06Ultrarapid metabolizers, reduced exposure and possible treatment failure.
- 25:11So when you have a drug-induced 2D6 inhibition,
- 25:15it can create a ~ "phenoconversion,"
- 25:18functionality converting a normal metabolizer into a poor metabolizer.
- 25:23See, what we've discovered is that some of these drugs can alter
- 25:27the genomic components of the CYP450 system.
- 25:31And this is now becoming a bigger deal than we knew about because
- 25:35we wondered why they couldn't-
- 25:36you know, some people take fluoxetine for instance and all of a sudden they build
- 25:40a tolerance or something. Well it may not be the case.
- 25:42It may be that they had a phenoconversion somewhere and they begin to
- 25:46become a very poor metabolizer of it as a result.
- 25:49Poor metabolizers may increase SSRI exposure and a greater risk of adverse effects,
- 25:53while ultra metabolizers may experience reduced efficacy.
- 25:57So you can see the pharmacogenomic dosing recommendations-
- 26:01and again UpToDate has some of these available,
- 26:04and you could see where you may have to increase or decrease the dose according
- 26:08to if you have that information on the genomics.
- 26:112C19, ~ again, you got citalopram and escitalopram
- 26:17and sertraline and diazepam and amitriptyline,
- 26:20then clomid, you got clomid in here,
- 26:22and then the inhibitors ~ are fluvoxamine and again you've got some of the H2
- 26:29drugs for the stomach. The important substrates,
- 26:32~ clozapine, olanzapine, duloxetine,
- 26:35caffeine, and these are the ones that we have to really look at for 1A2.
- 26:40The 1A2, the inducers is cigarette smoking,
- 26:43Carbamazepine, rifampin; the inhibitors are fluvoxamine,
- 26:48~ cipro, and ~
- 26:50several of your oral contraceptive ~ birth control tablets that you've had.
- 26:56Clinical pearls: smoking can substantially lower clozapine
- 26:59and olanzapine concentrations,
- 27:01as most of you are aware. Abrupt smoking cessation may rapidly increase serum
- 27:06concentrations, increasing the risk of sedation,
- 27:09seizures, hypotension, and other toxicities.
- 27:12If someone is smoking and a lot of people do smoke that are on these psychotropics
- 27:17~ and some want to quit and some want to decrease and those types of things.
- 27:21People have asked me, "Merrill,
- 27:23what about vaping?" Vaping can make this worse.
- 27:25So vaping actually increases the potency of the nicotine,
- 27:29the amount of nicotine consumed,
- 27:30and it can alter these
- 27:32concentrations. So one of the questions,
- 27:34make sure when you're doing your intake,
- 27:36when you're asking about smoking,
- 27:38you also include issues of vaping.
- 27:40The other pathways, we have the 2B6,
- 27:43its polymorphisms contribute to ~ the variability in wellbutrin
- 27:48and methadone metabolism, which may influence your treatment responses.
- 27:53I know in
- 27:53the clinic, LTP clinics, when I supervise them,
- 27:56we'd have to be aware of which medications we're doing because
- 27:59of this particular polymorphism.
- 28:002C9, although that's less important for most of your psychotropics,
- 28:06it's clinically relevant when psychiatric medications
- 28:08are prescribed with anticoagulants.
- 28:10So the 2C9 has to do with your blood thinners.
- 28:14And UGT pathways, valproate again inhibits this metabolism with
- 28:20Lamictal.
- 28:21Increasing Lamictal concentrations and increasing the risk
- 28:25of Stevens-Johnson syndrome. So that's a big one.
- 28:27That's a big one. You don't want Stevens-Johnson.
- 28:29It can be extremely dangerous.
- 28:31When
- 28:32we look at clinical application,
- 28:33so when initiating or modifying psychotropic therapies,
- 28:36you should review all medications,
- 28:38prescription, over the counter,
- 28:40herbals. Identify each medication's primary pathway.
- 28:44Screen for CYP inhibitors and inducers.
- 28:47Consider pharmacogenomic testing when indicated,
- 28:49particularly as it relates to 2D6 and 2C19.
- 28:54Make sure you have labs on ~ hepatic and renal function.
- 28:57Evaluate patient-specific factors such as aging,
- 29:00smoking status, and comorbid conditions.
- 29:03And also monitor for therapeutic response and adverse effects after medication
- 29:07changes.
- 29:08And I suggest y'all follow up within two to six weeks after you change
- 29:12a medication to see if they're really working.
- 29:14And you can do it by telemed. You can do it several different ways.
- 29:17But the thing about it is it's important that you follow up shortly after there's
- 29:21a medication. So let's look at high-risk combinations.
- 29:24And again, this is a quick review.
- 29:26These come out of FDA MedWatch.
- 29:28Most of you are a part of that.
- 29:30If not, you need to sign up for MedWatch.
- 29:32This is something FDA sends out every day.
- 29:34But the most dangerous combinations in psychiatry are methadone and alprazolam.
- 29:39Number one. If you got somebody on methadone and they are taking alprazolam
- 29:45in any dose, you've got a high risk of an overdose and other things.
- 29:49Buprenorphine and clonazepam. And so,
- 29:52you know, klonopin and and buprenorphine,
- 29:54they don't jive. It's not as dangerous as methadone and alprazolam.
- 29:58Oxycodone and diazepam.
- 30:00Alcohol and the benzodiazepines.
- 30:02Opioids and any Z drug, it could be Ambien or Sonata or whatever it may be.
- 30:08And the opioids and any kind of ~ gabapentin,
- 30:11perilin, ~ pregabalin, these things can create serious,
- 30:15serious depression and some overdose.
- 30:18What you find is that when you combine these,
- 30:21you will find profound sedation possibly,
- 30:23respiratory depression, coma, and overdose deaths.
- 30:27The FDA warns that opioids combined with benzodiazepines
- 30:30or other CNS depressants can slow breathing,
- 30:33coma, and death. It's not that you can't give them;
- 30:36it's just that they have to be given under supervision and they have
- 30:40to be closely monitored. That's the thing.
- 30:42That's the thing. It's not that they can't be given,
- 30:44because we detox people all the time by using a buprenorphine and a tranxene.
- 30:50But we check their blood pressure and everything twice a day,
- 30:52et cetera, et cetera. So you can do that.
- 30:54And then we got serotonin syndrome,
- 30:57which a lot of you have been inundated with serotonin syndrome.
- 31:00And I've been talking about serotonin syndrome,
- 31:02I guess when I started 20 years ago,
- 31:03people didn't know what it was,
- 31:04but now they're very well informed.
- 31:06Again, this is the list of antidepressants,
- 31:09monomamine oxidase inhibitors,
- 31:11antidepressants and tramadol, antidepressants and
- 31:15MDMA or ecstasy or dextromethorphan.
- 31:18But the thing about it is it can happen with any combination of anything that
- 31:23may affect the serotonergic system.
- 31:25The warning signs that you will see that has been reported,
- 31:28agitation, tremor, hyperreflexia,
- 31:31clonus, again, that movement in the hands and in the ankles,
- 31:36diaphoresis, fever, diarrhea, confusion.
- 31:40And it's caused by excessive serotonergic
- 31:42transmission and usually diagnosed clinically rather than by a laboratory test.
- 31:46It is usually observation. And a lot of you may have had that,
- 31:50and you will have that as you continue your practices and see these patients with
- 31:55these medications. Now let's talk about again the QT-prolonging psychotropics
- 31:59and other drugs. The reason I tell you that is it can lead to sudden cardiac death.
- 32:05And your combinations are here,
- 32:07methadone and citalopram. And they seem,
- 32:10you know, like they would seem fairly innocuous,
- 32:13but they're not. You've got ~ antipsychotics and macrolide antibiotics,
- 32:18~ you got Haldol and the fluoroquinolones,
- 32:21you've got antipsychotics and antiemetics that can be used,
- 32:27and then you can have TCAs and just an imbalance of
- 32:29potassium or sodium chloride. And the thing about it is,
- 32:33as most of y'all know, it has to do with the QRS complex.
- 32:37And you know, when we look at this cardiac conduction system,
- 32:41you know, we got the P wave, it's the atrial bump,
- 32:44you know, that's the SA node acting,
- 32:46and it's sending an electrical message to the AV node.
- 32:49And so you got the top of the heart going to the bottom of the heart,
- 32:52and then the PR interval onsets the atrial activity and then the ventricle activity.
- 32:57The QRS complex is the electrical ventricle activity,
- 33:00bump bump, and the ST-T segment is the repolarization of the ventricle,
- 33:05and the QT interval is the duration of the ventricle activity and recovery.
- 33:10And so what happens, y'all, simply put,
- 33:12Is that as we give these drugs,
- 33:14it widens, it widens that QT interval when you go from Q to T,
- 33:21in milliseconds. And what happens,
- 33:23it gets so wide that the heart says,
- 33:26"This ain't right, I'm gonna stop." And so when it stops,
- 33:29you can't restart the heart. You have sudden cardiac death.
- 33:33And the thing about it is it's something that you want to stay away from.
- 33:36It is something that is that serious.
- 33:39And that's why I keep talking about these;
- 33:40and a lot of these clinicians in these methadone and OTP clinics,
- 33:46I'm telling them, please be aware of the seriousness of this and what
- 33:50you need to do. So that's what we're talking,
- 33:52that area right there. So we have these abnormal intervals and
- 33:55the prolonged QTc causes premature action potentials during late phases
- 33:59of depolarization.
- 34:00This increases the risk of developing ventricular arrhythmias,
- 34:04including fatal ventricular fibrillation.
- 34:06We used to have, once you had venticular ~ VTAC,
- 34:10we call it, it was over. We couldn't stop the bottom of the heart.
- 34:13We now have medications that can do that if they're immediately applied.
- 34:17Higher rates of prolonged QTc is seen in females,
- 34:20older patients, high systolic blood pressure or heart rate,
- 34:24and short stature.
- 34:25Prolonged QTc is also associated with ECG findings of Torsades de Pointes,
- 34:29which is known to degenerate into ventricular fibrillation associated with high
- 34:34mortality rates. So you go into what we call the TDPs and then
- 34:39it goes into ventricular fibrillation and you can have an issue there.
- 34:42The risk factors for any kind of prolonged QTc is ~ hypokalemia,
- 34:48hypomagnesemia. So your electrolytes are imbalanced.
- 34:51You already may have bradycardia where you have an irregular heartbeat.
- 34:55You can be older, post-50, female,
- 34:58any history of cardiac disease,
- 35:01a high methadone dose, ~ CYP inhibitions and increasing drug levels.
- 35:06And again, it's one of these things that you need to look at your resources
- 35:10and keep up with these types of things.
- 35:12And that's the question that you come in with.
- 35:14When people come in and they're looking at it and you're dealing with
- 35:16antidepressants, that's why your medication history is so extremely important.
- 35:20And medication reconciliation is so important because they may have started
- 35:25~ you know, MOUD treatment, or they may have started AOUD treatment;
- 35:30they may have been placed on buprenorphine.
- 35:32~ And we have a lot of situations that are arising like that and clinicians
- 35:36are not quite catching it.
- 35:38So when we look at the 1A2 inhibitions and high-risk combinations,
- 35:43as we've already said before, clozapine,
- 35:45clozapine, clozapine, clozapine,
- 35:48clozapine. And all of the things that can change clozapine:
- 35:52antidepressants, antibiotics, caffeine escalation,
- 35:55this caffeine powder that people may be taking,
- 35:58~ smoking cessation, and I have some people stop smoking,
- 36:02start vaping, you know; carbamazepine,
- 36:04and those types of things. So when you see that,
- 36:07you have sedation, you have low blood pressure,
- 36:09delirium can be present, seizures,
- 36:12agranulocytosis risk with marrow-suppressing drugs,
- 36:17toxic clozapine levels after smoking.
- 36:19And then smoking induces the 1A2.
- 36:22So stopping smoking can increase clozapine and create a abnormal amount
- 36:27of clozapine, can be ~ again another risk.
- 36:30Lithium and renal function altering drugs.
- 36:33Lithium, as you all know, has a very narrow therapeutic index.
- 36:37So there's high-risk combinations that can lead to toxicities.
- 36:40And these are lithium and thiazide diuretics,
- 36:44if it be hydrodiural or diural,
- 36:47ACE inhibitors, ~ heart medications,
- 36:50ARBs, which are antiarrhythmic medications.
- 36:53Non-steroidal anti-inflammatories.
- 36:54Let me tell you non-steroidals.
- 36:56Ibuprofen is the classic worst non-steroidal for people to take,
- 37:01generally speaking, for lots of reasons.
- 37:03Drug interactions and other things,
- 37:05but it's commonly used. And people are not taking it as prescribed.
- 37:09Instead of taking one tablet, they're taking three,
- 37:11you know, because it's only 200 milligrams,
- 37:14whatever it may be. ~ And naproxen,
- 37:15Aleve, they're taking it. So these non-steroidals
- 37:19can create serious problems with a lot of these psychotropic medications.
- 37:23Dehydration, let me tell you, when I look at any person that's
- 37:28on a psychotropic medication, I want them to drink eight,
- 37:3212-ounce glasses of water a day.
- 37:35I want them fully hydrated. I want them fully hydrated.
- 37:38It's extremely important, not only for efficiency,
- 37:41but for safety reasons.
- 37:42And then lithium and low-sodium diets.
- 37:44You have to be careful, especially a lot of these diets,
- 37:47and lithium and antipsychotics.
- 37:49Now, some people have asked me,
- 37:50"Well, Merrill, what about the drugs,
- 37:52you know, the GLP-1s?" I'm working on that as we speak.
- 37:56We may have some problems with the GLP-1s with the interactions of some
- 38:00of these psychotropics. So the thing about it is,
- 38:03we didn't add it to that because I didn't have time to put it all together.
- 38:06When we look at these
- 38:08interactions of lithium: tremor,
- 38:10ataxia, confusion, GI upset, ~ nephrogenic diabetes insipidus,
- 38:16seizures, and coma. So you've got a list of ~ symptoms that do indicate there could
- 38:21be some serious problems. And then valporate and lamictal.
- 38:25Valproate simply inhibits lamictal's metabolism through the URT mechanism.
- 38:31The clinical risk is increased lamictal levels and increasing
- 38:34the possibility of Stevens-Johnson syndrome.
- 38:37And if you don't know what Stevens-Johnson syndrome looks like,
- 38:41please do me a favor. Go to YouTube and put Stevens-Johnson in there
- 38:46and look and see; it causes blisters on the palm of your hands and other things.
- 38:50So you will know the symptomology and what it may look like in
- 38:53the future because it's very serious,
- 38:55y'all. It can be life-threatening.
- 38:57Lamictal must also be started at lower doses and titrated more slowly when
- 39:00you use with valproate. You can use valproate and lamictal together,
- 39:04but you've got to be very sure about your dosing.
- 39:06Carbamazepine and psychotropics or MOUD,
- 39:10and Carbamazepine with methadone or buprenorphine,
- 39:13benzodiazepines, we can have very serious toxicities as a result of this.
- 39:19Carbamazepine
- 39:20has to be closely scrutinized.
- 39:22We also have it with oral contraceptives and anticoagulants,
- 39:26your blood thinners, especially these new ~ non-heparin-based synthetics that
- 39:32we use.
- 39:33And then polypharmacy. So when you combine antipsychotics,
- 39:36you create adverse risk burden by one,
- 39:40looking at your QT prolongations,
- 39:42your sedation,
- 39:43creates metabolic syndrome, your blood sugar changes,
- 39:46your triglyceride changes, those types of things,
- 39:49extrapyramidal symptomology, anticholinergic burden,
- 39:53as I mentioned, hyperprolactinemia,
- 39:57neurolectic malignant syndrome,
- 39:59and also what we call drug-induced Parkinson's.
- 40:01And so the thing about it is polypharmacy has got to be really scrutinized.
- 40:06I had some lady come in to the treatment center
- 40:10on four antipsychotics and three antidepressants.
- 40:13Yeah, it happens. And you know,
- 40:16there's lots of reasons for that.
- 40:17When we look at stimulants, monoamine oxidase,
- 40:19serotonergic drugs, and others,
- 40:21then we look at amphetamines that are being used for ADHD
- 40:25and then the monoamine oxidase inhibitors,
- 40:27which is a rare combination. Methamphetamine also has the same interaction
- 40:31as monoamine oxidase inhibitors.
- 40:32Any stimulant with other cocaine or methamphetamine.
- 40:36Stimulants and wellbutrin, and then stimulants and SNRIs.
- 40:39And then atomoxetine ~ and ~ strong 2D6 inhibitors.
- 40:45We also have what we call anticholinergic stacking.
- 40:47The burden is common
- 40:49with the antidepressants and some of the treatment mechanisms to treat side effects
- 40:54of the antidepressants. Clozapine and some of your anti-inflammatories,
- 40:59olanzapine, and diaphenylhydramine.
- 41:01Yeah, yeah, yeah, diaphenylhydramine.
- 41:04And then Paxil and hydroxyzine.
- 41:07So, when we want to evaluate these interactions between these psychotropics
- 41:11and SUDs, the objective is to be aware that if a person is on medications
- 41:15for an opioid use disorder, an alcohol use disorder,
- 41:18or cannabis use disorder, or tobacco use disorder,
- 41:21make sure you're aware what that may be.
- 41:23The core medications ~ are usually included in this list here that I've given
- 41:28you because these are approved medications of the FDA
- 41:31that they use: methadone, buprenorphine,
- 41:34naltrexone, acamprosate, disulfiram,
- 41:36nicotine replacement therapies,
- 41:38Chantix, wellbutrin, clonidine,
- 41:41~ gabapentin, Topamax, and et cetera.
- 41:44There's a book, ~ "TIP 63," made by SAMHSA.
- 41:47It's free online that has a whole list of these in the index that may
- 41:51be helpful to you if you care to look that up.
- 41:54So when you're evaluating the interaction between these psychotropics and all,
- 41:57one of the things you want to make sure that SSRIs and SNRIs are commonly used
- 42:01in patients also receiving medications for opioid use disorder.
- 42:05But interaction risk rises when methadone is combined with QT-prolonging
- 42:10antidepressants such as citalopram.
- 42:12So if somebody comes in and they're gonna be placed on ~ methadone,
- 42:16and if they're on the citalopram,
- 42:18I'm gonna want that to be changed before they're placed on that medication
- 42:21if possible. In dual-diagnosis care,
- 42:24antipsychotics are often necessary,
- 42:25but the greatest safety risk for QT prolongation,
- 42:28sedation, metabolic burden, and smoking-related 1A2 changes.
- 42:33Again, the smoking has a lot to do with how these people interact and what
- 42:38the dose should be.
- 42:39Mood stabilizers, ~ Carbamazepine,
- 42:42as I've mentioned to you before,
- 42:43will interact with a lot of the treatment drugs that are used
- 42:46for substance use disorders. And then benzodiazepines are classics.
- 42:51And so the FDA and ASAM, American Society of Addiction Medicine,
- 42:55emphasize that methadone or buprenorphine should not automatically
- 42:59be withheld from patients taking benzos or sedative hypnotics.
- 43:03Instead, clinicians should be careful.
- 43:07Medication management because of untreated OUD carries substantial mortality risk.
- 43:12So you've got to be careful, not you don't want to take them off,
- 43:15you want to make sure you supervise them appropriately.
- 43:17You need to assess dose duration,
- 43:19alcohol use, sleep apnea is important,
- 43:22COPD, overdose history, and other sedatives.
- 43:26You need to educate the patient,
- 43:27prescribing naloxone when appropriate,
- 43:30avoid abrupt benzodiazepine discontinuation,
- 43:33and coordinate care with your prescribers.
- 43:35And that's extremely important.
- 43:37And y'all are learning how you do that.
- 43:38And you want to evaluate these interactions between stimulants and SUD medications.
- 43:45ADHD treatment should not be automatically denied for patients with substance
- 43:49use disorders, but prescribing may require careful diagnosis,
- 43:52monitoring, diversion control,
- 43:54and attention to stimulant-induced anxiety,
- 43:56insomnia, hypertension, and psychosis.
- 43:58So you got to be aware. And then
- 44:00methadone and QT prolongation.
- 44:02Let's look at the algorithm. Basically it's very simple,
- 44:04y'all. You want to confirm your diagnosis as best you can.
- 44:07You want to do medication reconciliation as best you can.
- 44:11If you you've been trained in it;
- 44:13if not, you need to be trained in it.
- 44:15If not, a good psychiatric pharmacist is more than happy to help you do that,
- 44:19or a psychiatric nurse practitioner.
- 44:21You want to try to evaluate best you can the pharmacokinetic risk,
- 44:25and then the pharmacodynamic risk.
- 44:27The pharmacokinetic is body-to-drug,
- 44:29and then drug-to-body is the pharmacodynamics.
- 44:31And then evaluate patient-specific risk factors.
- 44:34Consider pharmacogenomic testing if possible.
- 44:37Obtain baseline monitoring, which is good labs.
- 44:40You want a good standard lab. You want to start low and go slow.
- 44:43It's going to involve a lot of patient education.
- 44:46I will tell you, being in the world of substance use disorder and mental illness
- 44:50for many years, educating patients to how to take medications so they
- 44:54can comply is an ongoing process.
- 44:56And then of course ongoing monitoring.
- 44:58That's the biggest thing when you want to do that.
- 45:00You want to perform the medication reconciliation before every prescribing
- 45:04decision, so you want to do that soon in the intake.
- 45:07You want to evaluate both the pharmacokinetic and
- 45:10the pharmacodynamic interaction risk.
- 45:12You want to consider the smoking status,
- 45:13the hepatic function, renal function,
- 45:16age, pregnancy, comorbid metal illness.
- 45:18You want to use pharmacogenomic testing selectively to inform medication selection
- 45:22and dosing if necessary. Start with the lowest effective dose
- 45:26and titrate cautiously. Engage patients through education
- 45:29and shared decision-making.
- 45:30And continuously reassess the need for each medication
- 45:33and simplify regimens whenever possible.
- 45:36These are your ~ references. I hope they are helpful to you if you're interested
- 45:41in looking and using them. There's a good many of them because there's
- 45:46a lot of information out here that are very,
- 45:49very good ~ and very helpful. And it's something that I hope that you will use,
- 45:53especially from the FDA. The FDA is very good.
- 45:56UpToDate is very good, and other clinical resources are also available.
- 46:00I think there's three or four pages of these as you can see.
- 46:03~ Five pages, I mean; there's a lot of information ~ having to do that.
- 46:08These are not things that I can keep all in my head at one time,
- 46:11as y'all probably well know. But I did want y'all to definitely have this insight
- 46:16into how important this particular mechanism and these mechanisms are
- 46:22to keep up with. And they change on a month-to-month basis.
- 46:26That's why ~ MedWatch is extremely important to be a part of so that you
- 46:31can keep up with that. And ~ maybe,
- 46:34you know, you'll understand
- 46:36as you get more involved with clinical practice in these medications.
- 46:39And then again, we got a whole new set.
- 46:41You know, the GLP-1s are coming and I've got to do something.
- 46:44We've got the psychedelics, they're coming.
- 46:46~ You know, this could be, ~ to be honest with you,
- 46:50in pharmacy school it's a whole semester course.
- 46:53So it won't be something that y'all may see,
- 46:56but it is something that we have to deal with on a regular basis every day.
- 46:59I'm glad y'all were with me tonight.
- 47:01Thank you, Dr. Norton, for a great presentation.
- 47:03Well, thank you. You're welcome,
- 47:04George. You're welcome. So I'm very happy to do what I can.
- 47:08And those of you who want to learn more ~ in MSCP programs like ours,
- 47:12we cover all of the information that Dr.
- 47:16Norton talked about. At Alliant,
- 47:18Dr. Norton is teaching
- 47:20~ about half of one of our courses that's ~ devoted to addictions.
- 47:25So we look forward to having you.
- 47:28So if you're interested in this and want to learn more,
- 47:31we're here. Please, please let us know.